Tonix Pharmaceuticals and Bilthoven Biologicals to Advance Development of TNX-801
DENVER, Colo., Aug 26, 2024 (247marketnews.com)- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) stated that it would collaborate with Bilthoven Biologicals (BBio) to advance TNX-801, a live replicating, attenuated virus vaccine based on horsepox in preclinical development to prevent mpox and smallpox.
Seth Lederman, M.D., CEO of Tonix Pharmaceuticals, commented, “TNX-801 is administered with a single dose, which we believe will improve acceptance and eliminate partial vaccination compared to the current two-dose regimens. We believe TNX-801 can be rapidly scaled up for manufacturing and can be distributed and stored without a costly and cumbersome ultra-cold supply chain. TNX-801 has the potential to make a global impact on mpox and the risk of smallpox because of its durable T-cell immune response, the potential to manufacture at scale, and the use of a lower dose than non-replicating vaccines.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com